Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADAR-1 CRPC
2024-518623-30-00Phase 4Authorised
- Sponsor
- Policlinico Gemelli
- Start
- Nov 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Docetaxel plus prednisone, Abiraterone acetate plus prednisone and Enzalutamide (3 arms). Primary endpoint: Radiographic progression-free survival (rPFS) rate at 9 months. Planned start Nov 2024; status: authorised.
02
Drugs
docetaxelabirateroneenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2024-518623-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518623-30-00.